biotech
biotech Articles
More and more companies are joining the fight against the coronavirus. Quest Diagnostics is one of the newest to make this list.
Published:
Arcturus Therapeutics stock jumped on Wednesday after the company announced that it would be joining the fight against the latest coronavirus.
Published:
Peanut allergy is a serious and dangerous, but one biotech may hold the answer that could lead to to a 100% or 200% gain as its peanut allergy drug is expected to become more than just a blockbuster...
Published:
Stealth Bio stock more than doubled on Tuesday after the company announced a critical update from the FDA.
Published:
Co-Diagnostics is a small-cap stock that is far from a household name, but it has received much added exposure of late.
Published:
The analysts at its underwriting firms are quite positive on Beam Therapeutics, now that its post-IPO quiet period has come to an end.
Published:
Last Updated:
Forty Seven shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences. But is Gildead paying too much?
Published:
One of the biggest concerns in the financial markets at this time is that governments and central banks have few obvious policy tools to help keep their economies going if what was seen in China...
Published:
These stocks that are either defensive in general or are defying the big drop because they have some aspect of their business that might be immune to daily scares or because they are potential...
Published:
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Novavax shares made a big step forward on Wednesday after the firm provided an update on its treatment for COVID-19.
Published:
Gilead Sciences stock surged while the broader market was battered on reports that a senior official from the World Health Organization said that Gilead's remdesivir may currently be the best bet on...
Published:
The broad markets are getting crushed on Monday on renewed fears of the spread of the coronavirus (Covid-19). But a handful of stocks were acting as a natural hedge to the virus news.
Published:
Karyopharm Therapeutics shares made a handy gain on Wednesday after the firm secured a key FDA nod for its relapsed or refractory diffuse large B-cell lymphoma treatment.
Published:
Investors are not used to hearing is the word "biotech" used in the same sentence as anything to do with Warren Buffett and Berkshire Hathaway. Yet the portfolio managers have purchased shares of...
Published: